Rhythm Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Revenue	130.13	77.43	23.64	3.15	-	Upgrade
Revenue Growth (YoY)	68.06%	227.56%	649.46%	-	-	Upgrade
Cost of Revenue	13.37	9.3	2.13	0.6	-	Upgrade
Gross Profit	116.76	68.13	21.51	2.56	-	Upgrade
Selling, General & Admin	144.3	117.53	92.03	68.49	46.13	Upgrade
Research & Development	237.96	134.95	108.63	104.13	90.45	Upgrade
Operating Expenses	382.26	252.48	200.66	172.61	136.58	Upgrade
Operating Income	-265.5	-184.36	-179.16	-170.06	-136.58	Upgrade
Interest Expense	-20.6	-13.89	-5.2	-	-	Upgrade
Interest & Investment Income	14.71	13.95	4.03	0.45	2.58	Upgrade
Other Non Operating Income (Expenses)	11.14	0.19	0.25	100	-	Upgrade
EBT Excluding Unusual Items	-260.26	-184.11	-180.08	-69.61	-134	Upgrade
Gain (Loss) on Sale of Investments	-	-	-1.04	-	-	Upgrade
Pretax Income	-260.26	-184.11	-181.12	-69.61	-134	Upgrade
Income Tax Expense	0.35	0.56	-	-	-	Upgrade
Net Income	-260.6	-184.68	-181.12	-69.61	-134	Upgrade
Preferred Dividends & Other Adjustments	3.97	-	-	-	-	Upgrade
Net Income to Common	-264.57	-184.68	-181.12	-69.61	-134	Upgrade
Shares Outstanding (Basic)	61	58	52	50	44	Upgrade
Shares Outstanding (Diluted)	61	58	52	50	44	Upgrade
Shares Change (YoY)	5.76%	10.65%	5.08%	12.40%	21.15%	Upgrade
EPS (Basic)	-4.34	-3.20	-3.47	-1.40	-3.04	Upgrade
EPS (Diluted)	-4.34	-3.20	-3.47	-1.40	-3.04	Upgrade
Free Cash Flow	-113.88	-136.2	-173.71	-146.44	-122.19	Upgrade
Free Cash Flow Per Share	-1.87	-2.36	-3.33	-2.95	-2.77	Upgrade
Gross Margin	89.73%	87.99%	90.98%	81.01%	-	Upgrade
Operating Margin	-204.04%	-238.10%	-757.92%	-5391.85%	-	Upgrade
Profit Margin	-203.32%	-238.52%	-766.22%	-2207.10%	-	Upgrade
Free Cash Flow Margin	-87.51%	-175.91%	-734.87%	-4642.90%	-	Upgrade
EBITDA	-263.94	-182.6	-177.49	-168.9	-135.89	Upgrade
EBITDA Margin	-202.83%	-235.83%	-	-	-	Upgrade
D&A For EBITDA	1.56	1.76	1.67	1.16	0.69	Upgrade
EBIT	-265.5	-184.36	-179.16	-170.06	-136.58	Upgrade
EBIT Margin	-204.04%	-238.10%	-	-	-	Upgrade
Revenue as Reported	130.13	77.43	23.64	3.15	-	Upgrade

Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q